| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 |
|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||
Current assets: | |||||||||
Cash | |||||||||
- | - | - | - | - | - | - | - | - | 63,533 |
Cash and cash equivalents | |||||||||
23,432 | 44,290 | 31,379 | 24,261 | 21,913 | 20,800 | 15,842 | 45,736 | 53,102 | - |
Marketable securities | |||||||||
25,298 | 15,120 | 0 | 3,995 | 8,966 | 18,412 | 23,339 | - | - | 0 |
Accounts receivable | |||||||||
605 | 755 | 610 | 522 | - | - | - | - | - | - |
Restricted cash, short term | |||||||||
- | - | - | 50 | 50 | 50 | 50 | 50 | - | 50 |
Certificate of deposit | |||||||||
- | - | - | - | - | - | - | - | 50 | - |
Research and development contract advances | |||||||||
- | - | - | - | - | - | - | - | 1,383 | - |
Prepaid expenses and other current assets | |||||||||
1,855 | 860 | 1,001 | 1,040 | 1,039 | 1,347 | 1,380 | 3,464 | 884 | 1,255 |
Deposits, short-term | |||||||||
- | - | - | - | - | - | - | - | 510 | 225 |
Total current assets | |||||||||
51,190 | 61,025 | 32,990 | 29,868 | 31,968 | 40,610 | 40,611 | 49,250 | 55,929 | 65,065 |
Property and equipment, net | |||||||||
1,794 | 1,847 | 2,031 | 2,208 | 2,595 | 2,781 | 2,869 | 2,763 | 2,423 | 1,690 |
Operating lease right-of-use | |||||||||
4,339 | 5,337 | 6,656 | 7,679 | 8,691 | - | - | - | - | - |
Deposits | |||||||||
2,572 | 2,572 | 2,589 | 1,013 | 1,013 | 1,012 | - | - | - | - |
Deposits | |||||||||
- | - | - | - | - | - | 777 | 777 | 776 | - |
Trademark | |||||||||
- | - | - | - | - | - | 175 | 175 | 175 | - |
Restricted cash, long term | |||||||||
150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | - | - |
Other long term assets | |||||||||
604 | 674 | 793 | 838 | 771 | 808 | - | - | - | 198 |
Long-term service contract | |||||||||
- | - | - | - | - | - | - | - | 23 | - |
Total assets | |||||||||
60,649 | 71,605 | 45,209 | 41,756 | 45,188 | 45,363 | 44,582 | 53,114 | 59,326 | 66,953 |
Liabilities and Stockholders’ Equity | |||||||||
Current liabilities: | |||||||||
Accounts payable | |||||||||
1,740 | 883 | 1,178 | 2,289 | 2,893 | 2,035 | 997 | 546 | - | 1,659 |
Accrued expenses | |||||||||
1,144 | 2,227 | 1,555 | 2,580 | 2,149 | 1,788 | 2,268 | 1,124 | - | 1,151 |
Research and development contract liability, current portion | |||||||||
4,691 | 4,097 | 3,225 | 2,363 | 1,887 | 2,011 | 1,095 | 1,218 | - | 2,500 |
Deferred rent | |||||||||
- | - | - | - | - | 381 | 225 | 75 | - | 36 |
Operating lease liability, current portion | |||||||||
4,515 | 4,448 | 4,434 | 4,036 | 3,644 | - | - | - | - | - |
Total current liabilities | |||||||||
12,090 | 11,655 | 10,392 | 11,268 | 10,573 | 6,216 | 4,585 | 2,963 | - | 5,346 |
Research and development contract liability, net of current portion | |||||||||
3,129 | 4,018 | 5,185 | 6,420 | 4,930 | 5,174 | 593 | 919 | - | - |
Operating lease liability, net of current portion | |||||||||
194 | 1,348 | 2,610 | 3,787 | 4,947 | - | - | - | - | - |
Accounts payable and accrued expenses | |||||||||
- | - | - | - | - | - | - | - | 1,166 | - |
Accrued compensation and related expenses | |||||||||
- | - | - | - | - | - | - | - | 259 | - |
Research and development collaboration agreement deferred credit | |||||||||
- | - | - | - | - | - | - | - | 2,309 | - |
Research and development contract liabilities | |||||||||
- | - | - | - | - | - | - | - | 341 | - |
Deferred rent | |||||||||
- | - | - | - | - | - | - | - | 9 | - |
Total liabilities | |||||||||
15,413 | 17,021 | 18,187 | 21,475 | 20,450 | 11,391 | 5,178 | 3,882 | 4,084 | 5,346 |
Commitments and Contingencies (Note 14) | |||||||||
- | - | - | - | - | - | - | - | 0 | - |
Stockholders’ equity: | |||||||||
Preferred Stock, $0.001 par value; 10,000,000 shares authorized and 0 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively | |||||||||
- | - | - | - | - | - | 0 | 0 | 0 | - |
Common stock, $0.001 par value; 50,000,000 shares authorized; 26,575,959 and 26,562,178 shares issued and outstanding, at March 31, 2020 and December 31, 2019, respectively | |||||||||
27 | 26 | 23 | 21 | 21 | 20 | 20 | 20 | 20 | 19 |
Common stock to be issued | |||||||||
- | - | - | - | - | - | - | - | - | 0 |
Additional paid in capital | |||||||||
166,278 | 163,068 | 126,582 | 112,852 | 107,788 | 105,762 | 99,584 | 96,841 | 95,566 | 94,407 |
Accumulated other comprehensive income/ (loss) | |||||||||
249 | -10 | - | - | -3 | -10 | -20 | - | - | - |
Accumulated deficit | |||||||||
-121,318 | -108,500 | -99,583 | -92,592 | -83,068 | -71,801 | -60,180 | -47,629 | -40,344 | -32,820 |
Total stockholders’ equity | |||||||||
45,236 | 54,584 | 27,022 | 20,281 | 24,738 | 33,971 | 39,404 | 49,232 | 55,242 | 61,607 |
Total liabilities and stockholders’ equity | |||||||||
60,649 | 71,605 | 45,209 | 41,756 | 45,188 | 45,363 | 44,582 | 53,114 | 59,326 | 66,953 |